The Journal of Pain
Volume 11, Issue 9 , Pages 807-829 , September 2010

Opioid Pharmacotherapy for Chronic Non-Cancer Pain in the United States: A Research Guideline for Developing an Evidence-Base

  • C. Richard Chapman

      Affiliations

    • Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah
    • Corresponding Author InformationAddress reprint requests to C. Richard Chapman, PhD, Pain Research Center, Department of Anesthesiology, University of Utah, 615 Arapeen Drive, Suite 200, Salt Lake City, UT 84108.
    • ,
  • David L. Lipschitz

      Affiliations

    • Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah
    • ,
  • Martin S. Angst

      Affiliations

    • Department of Anesthesiology, Stanford University, Palo Alto, California
    • ,
  • Roger Chou

      Affiliations

    • Internal Medicine and Geriatrics, School of Medicine, Oregon Health & Science University, Portland, Oregon
    • ,
  • Richard C. Denisco

      Affiliations

    • National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, NIH, Bethesda, Maryland
    • ,
  • Gary W. Donaldson

      Affiliations

    • Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah
    • ,
  • Perry G. Fine

      Affiliations

    • Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah
    • ,
  • Kathleen M. Foley

      Affiliations

    • Pain & Palliative Care Service, Memorial Sloan Kettering Cancer Center, New York, New York
    • ,
  • Rollin M. Gallagher

      Affiliations

    • Departments of Psychiatry and Anesthesiology and Critical Care, Penn Pain Medicine Center, University of Pennsylvania School of Medicine, and Philadelphia VA Medical Center, Philadelphia, Pennsylvania
    • ,
  • Aaron M. Gilson

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    • ,
  • J. David Haddox

      Affiliations

    • Risk Management & Health Policy, Purdue Pharma, Stamford, Connecticut
    • ,
  • Susan D. Horn

      Affiliations

    • Institute for Clinical Outcomes Research (ICOR) and International Severity Information Systems, Inc. (ISIS), Department of Medical Informatics, University of Utah School of Medicine, Salt Lake City, Utah
    • ,
  • Charles E. Inturrisi

      Affiliations

    • Department of Pharmacology, Joan and Sanford I. Weill Medical School of Cornell University, New York, New York
    • Pain & Palliative Care Service, Memorial Sloan Kettering Cancer Center, New York, New York
    • ,
  • Susan S. Jick

      Affiliations

    • Department of Epidemiology, Boston University, Boston, Massachusetts
    • ,
  • Arthur G. Lipman

      Affiliations

    • Department of Pharmacotherapy, L.S. Skaggs Pharmacy, University of Utah, Salt Lake City, Utah
    • ,
  • John D. Loeser

      Affiliations

    • Department of Neurological Surgery, University of Washington, Seattle, Washington
    • ,
  • Meredith Noble

      Affiliations

    • ECRI Institute, Plymouth Meeting, Pennsylvania
    • ,
  • Linda Porter

      Affiliations

    • National Institute of Neurological Disorders and Stroke, Systems and Cognitive Neuroscience, National Institutes of Health, Bethesda, Maryland
    • ,
  • Michael C. Rowbotham

      Affiliations

    • Pain Clinical Research Center, University of California San Francisco, San Francisco, California
    • ,
  • Karen M. Schoelles

      Affiliations

    • ECRI Institute, Plymouth Meeting, Pennsylvania
    • ,
  • Dennis C. Turk

      Affiliations

    • Department of Anesthesiology, University of Washington, Seattle, Washington
    • ,
  • Ernest Volinn

      Affiliations

    • Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah
    • ,
  • Michael R. Von Korff

      Affiliations

    • Center for Health Studies Group Health Cooperative, Seattle, Washington
    • ,
  • Lynn R. Webster

      Affiliations

    • Lifetree Pain Clinic, Salt Lake City, Utah
    • ,
  • Constance M. Weisner

      Affiliations

    • Department of Psychiatry, University of California San Francisco, San Francisco, California

References: 

  1. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–2222
  2. Ahmedzai SH, Boland J. Opioids for chronic pain: Molecular and genomic basis of actions and adverse effects. Curr Opin Support Palliat Care. 2007;1:117–125
  3. Alley LG. The influence of an organizational pain management policy on nurses' pain management practices. Oncol Nurs Forum. 2001;28:867–874
  4. Anderson DT, Muto JJ. Duragesic transdermal patch: Postmortem tissue distribution of fentanyl in 25 cases. J Anal Toxicol. 2000;24:627–634
  5. Angst MS, Clark JD. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology. 2006;104:570–587
  6. Atkinson D, Dunne A, Parker M. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user. Anaesthesia. 2007;62:952–955
  7. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003;98:1415–1421
  8. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943–1953
  9. Bassler D, Ferreira-Gonzalez I, Briel M, Cook DJ, Devereaux PJ, Heels-Ansdell D, et al. Systematic reviewers neglect bias that results from trials stopped early for benefit. J Clin Epidemiol. 2007;60:869–873
  10. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120
  11. Berry DA. The Bayesian principle: Can we adapt?. Stroke. 2005;36:1623–1624
  12. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27–36
  13. Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain. 2006;22:667–676
  14. Bonica JJ, Loeser JD. History of pain concepts and therapies. In:  Loeser JD,  Butler SH,  Chapman CR editor. Bonica's Management of Pain. 3rd ed. New York, NY: Lippincott Williams & Wilkins; 2001;p. 3–16
  15. Bradshaw DH, Empy C, Davis P, Lipschitz D, Nakamura Y, Chapman CR: Trends in funding for research on pain: A report on the National Institutes Of Health grant awards over the years 2003 to 2007. J Pain 9:1077-1087, 1087 e1071-1078, 2008
  16. Breckenridge J, Clark JD. Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. J Pain. 2003;4:344–350
  17. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006;2:137–146
  18. Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130:144–156
  19. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9:360–372
  20. Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain. 2005;21:345–352
  21. Carroll IR, Angst MS, Clark JD. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med. 2004;29:576–591
  22. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. 2007;91:199–211
  23. Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J. Altered quantitative sensory testing outcome in subjects with opioid therapy. Pain. 2009;143:65–70
  24. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:147–159
  25. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130
  26. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:131–146
  27. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology. 2006;105:334–337
  28. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479–496
  29. Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002;23:131–137
  30. Colpaert FC. Mechanisms of opioid-induced pain and antinociceptive tolerance: Signal transduction. Pain. 2002;95:287–288
  31. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, et al. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol. 2004;28:616–624
  32. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006;79:316–324
  33. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–384
  34. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36
  35. de Leon-Casasola OA, Lema MJ. Epidural bupivacaine/sufentanil therapy for postoperative pain control in patients tolerant to opioid and unresponsive to epidural bupivacaine/morphine. Anesthesiology. 1994;80:303–309
  36. Deer TR, Kim C, Bowman R, Tolentino D, Stewart C, Tolentino W. Intrathecal ziconotide and opioid combination therapy for noncancer pain: An observational study. Pain Physician. 2009;12:E291–E296
  37. Donaldson G. Patient-reported outcomes and the mandate of measurement. Qual Life Res. 2008;17:1303–1313
  38. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121
  39. Ehrlich GE. Back pain. J Rheumatol Suppl. 2003;67:26–31
  40. Ersek M, Cherrier MM, Overman SS, Irving GA. The cognitive effects of opioids. Pain Manag Nurs. 2004;5:75–93
  41. Etzioni RD, Kadane JB. Bayesian statistical methods in public health and medicine. Annu Rev Public Health. 1995;16:23–41
  42. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: A validation study. J Pain Symptom Manage. 2003;25:406–411
  43. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287–294
  44. Federation of State Medical Boards of the United States Inc. Model guidelines for the use of controlled substances for the treatment of pain. Euless, TX: Federation of State Medical Boards of the United States Inc; 1998;
  45. Federation of State Medical Boards of the United States Inc. Model policy for the use of controlled substances for the treatment of pain. Dallas, TX: Federation of State Medical Boards of the United States Inc; 2004;
  46. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444–459
  47. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother. 2002;16:9–28
  48. Fishman SM. Responsible opioid prescribing: A physician's guide. Washington, DC: Waterford Life Sciences; 2007;
  49. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573–582
  50. Franklin GM, Mai J, Wickizer T, Turner JA, Fulton-Kehoe D, Grant L. Opioid dosing trends and mortality in Washington State workers' compensation, 1996-2002. Am J Ind Med. 2005;48:91–99
  51. Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM. Early opioid prescription and subsequent disability among workers with back injuries: The Disability Risk Identification Study Cohort. Spine. 2008;33:199–204
  52. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. Cmaj. 2006;174:1589–1594
  53. Gallagher R. Opioids in chronic pain management: Navigating the clinical and regulatory challenges. J Fam Pract. 2004;53:S23–S32
  54. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. Criteria for Distinguishing Effectiveness from Efficacy Trials in Systematic Reviews. Technical Review 12 (Prepared by the RTI-International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016). AHRQ Publication No. 06-0046. Rockville, MD: Agency for Healthcare Research and Quality; 2006;
  55. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59:1040–1048
  56. Gilson AM, Joranson DE, Maurer MA. Improving state pain policies: Recent progress and continuing opportunities. CA Cancer J Clin. 2007;57:341–353
  57. Gilson AM, Jornson DE, Maurer MS. Improving state medical board policies: Influence of a model. Journal of Law. Medicine & Ethics. 2003;31:119–129
  58. Gilson AM, Maurer MA, Joranson DE. State policy affecting pain management: Recent improvements and the positive impact of regulatory health policies. Health Policy. 2005;74:192–204
  59. Gilson AM, Maurer MA, Joranson DE. State medical board members' beliefs about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain. 2007;8:682–691
  60. Graham JK, Hanzlick R. Accidental drug deaths in Fulton County, Georgia, 2002: characteristics, case management and certification issues. Am J Forensic Med Pathol. 2008;29:224–230
  61. Greenlee RT, Coleman LA, Nelson AF, Selby JV: Partnerships in translation: advancing research and clinical care. The 14th Annual HMO Research Network Conference, April 13-16, 2008, Minneapolis, Minnesota. Clin Med Res 6:109-112, 2008
  62. Guglielmo WJ: Helping patients. Protecting yourself. Med Econ 81:69-70, 72-64, 76, 2004
  63. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613–2620
  64. Hoffmann DE, Tarzian AJ. Achieving the right balance in oversight of physician opioid prescribing for pain: the role of state medical boards. J Law Med Ethics. 2003;31:21–40
  65. Horn SD, Bender SA, Ferguson ML, Smout RJ, Bergstrom N, Taler G, et al. The National Pressure Ulcer Long-Term Care Study: pressure ulcer development in long-term care residents. J Am Geriatr Soc. 2004;52:359–367
  66. Horn SD, DeJong G, Smout RJ, Gassaway J, James R, Conroy B. Stroke rehabilitation patients, practice, and outcomes: is earlier and more aggressive therapy better?. Arch Phys Med Rehabil. 2005;86:S101–S114
  67. Horn SD, Wright HL, Couperus JJ, Rhodes RS, Smout RJ, Roberts KA, et al. Association between patient-controlled analgesia pump use and postoperative surgical site infection in intestinal surgery patients. Surg Infect (Larchmt). 2002;3:109–118
  68. Howard KI, Moras K, Brill PL, Martinovich Z, Lutz W. Evaluation of psychotherapy. Efficacy, effectiveness, and patient progress. Am Psychol. 1996;51:1059–1064
  69. Hudson TJ, Edlund MJ, Steffick DE, Tripathi SP, Sullivan MD. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manage. 2008;36:280–288
  70. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci. 2005;26:311–317
  71. Joranson DE, Gilson AM. Pharmacists' knowledge of and attitudes toward opioid pain medications in relation to federal and state policies. J Am Pharm Assoc (Wash). 2001;41:213–220
  72. Kadiev E, Patel V, Rad P, Thankachan L, Tram A, Weinlein M, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008;4:77–91
  73. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380
  74. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223–246
  75. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–1239
  76. Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications?. J Addict Dis. 2008;27:5–9
  77. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31:206–219
  78. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297:249–251
  79. Li Y, Wang X, Tian S, Guo CJ, Douglas SD, Ho WZ. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis. 2002;185:118–122
  80. Lipman AG, Jackson KC. Opioids. In:  Warfield C,  Bajwa Z editor. Principles and Practice of Pain Management. 2nd ed. New York, NY: McGraw Hill; 2003;
  81. Loeser JD. Economic implications of pain management. Acta Anaesthesiol Scand. 1999;43:957–959
  82. Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006;6:200–210
  83. Lu CY. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract. 2009;63:691–697
  84. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11:S63–S88
  85. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:116–127
  86. McCandless LC, Gustafson P, Austin PC. Bayesian propensity score analysis for observational data. Stat Med. 2009;28:94–112
  87. McLellan AT, Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA. 2008;300:2672–2673
  88. Merskey H. Variable meanings for the definition of disease. J Med Philos. 1986;11:215–232
  89. Milligan K, Lanteri-Minet M, Borchert K, Helmers H, Donald R, Kress HG, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain. 2001;2:197–204
  90. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657–662
  91. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1025–1035
  92. Moinpour CM, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data?. J Natl Cancer Inst Monogr. 2007;31–38
  93. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, et al. Southwest Oncology G: Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008;26:112–120
  94. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203–2209
  95. Murray Thomson W, Poulton R, Mark Broadbent J, Al-Kubaisy S. Xerostomia and medications among 32-year-olds. Acta Odontol Scand. 2006;64:249–254
  96. Nagashima M, Katoh R, Sato Y, Tagami M, Kasai S, Ikeda K. Is there genetic polymorphism evidence for individual human sensitivity to opiates?. Curr Pain Headache Rep. 2007;11:115–123
  97. NCHS. Health, United States, 2006 with chartbook on trends in the health of Americans. Hyattsville: National Center for Health Statistics; 2006;
  98. Neumayer LA, Smout RJ, Horn HG, Horn SD. Early and sufficient feeding reduces length of stay and charges in surgical patients. J Surg Res. 2001;95:73–77
  99. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008;35:214–228
  100. Office of Applied Studies Substance Abuse and Mental Health Services Administration (SAMHSA): The NSDUH Report: Exposure to Substance Use Prevention Messages and Substance Use among Adolescents: 2002 to 2007. Rockville, MD 2009
  101. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7:225–235
  102. Pain & Policy Studies Group. Achieving Balance in State Pain Policy: A Progress Report Card. Fourth ed.. Madison, WI: University of Wisconsin Paul P. Carbone Comprehensive Cancer Center; 2008;
  103. Pain & Policy Studies Group. Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation. Fifth ed.. Madison, WI: University of Wisconsin Paul P. Carbone Comprehensive Cancer Center; 2008;
  104. Paulozzi LJ, Annest JL. US data show sharply rising drug-induced death rates. Inj Prev. 2007;13:130–132
  105. Pimentel L, Mayo D. Chronic methadone therapy complicated by torsades de pointes: a case report. J Emerg Med. 2008;34:287–290
  106. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11:203–217
  107. Portenoy RK, Farrar JT, Backonja MM, Cleeland CS, Yang K, Friedman M, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299
  108. Potter M, Schafer S, Gonzalez-Mendez E, Gjeltema K, Lopez A, Wu J, et al. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco J Fam Pract. 2001;50:145–151
  109. Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev:CD004847, 2004
  110. Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain - new perspective of opioid-induced hyperalgesia. Pain. 2008;139:431–438
  111. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain. 1995;61:195–201
  112. Rasmussen C, Leboeuf-Yde C, Hestbaek L, Manniche C. Poor outcome in patients with spine-related leg or arm pain who are involved in compensation claims: a prospective study of patients in the secondary care sector. Scand J Rheumatol. 2008;37:462–468
  113. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009;62:1226–1232
  114. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009;62:1233–1241
  115. Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008;27:4678–4721
  116. Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008;9:905–933
  117. Rowbotham MC, Lindsey CD. How effective is long-term opioid therapy for chronic noncancer pain?. Clin J Pain. 2007;23:300–302
  118. Sims SA, Snow LA, Porucznik CA. Surveillance of methadone-related adverse drug events using multiple public health data sources. J Biomed Inform. 2007;40:382–389
  119. Sjogren P, Christrup LL, Petersen MA, Hojsted J. Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain. 2005;9:453–462
  120. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429–444
  121. Steiner GA. Strategic planning: what every manager must know. New York, NY: Free Press; 1979;
  122. Strassels SA. Cognitive effects of opioids. Curr Pain Headache Rep. 2008;12:32–36
  123. Thompson JG, Baker AM, Bracey AH, Seningen J, Kloss JS, Strobl AQ, et al. Fentanyl concentrations in 23 postmortem cases from the hennepin county medical examiner's office. J Forensic Sci. 2007;52:978–981
  124. Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, et al. Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr. 2004;37:1423–1430
  125. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11:S5–S62
  126. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain. 2008;137:276–285
  127. Uhl GR, Drgon T, Johnson C, Li CY, Contoreggi C, Hess J, et al. Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify “connectivity constellation” and drug target genes with pleiotropic effects. Ann N Y Acad Sci. 2008;1141:318–381
  128. United States General Accounting Office: Prescription drug monitoring: States can readily identify illegal sales and use of controlled substances. In: United States General Accounting Office, ed. Washington, DC: GAO/HRD 1992:92-115
  129. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99:221–227
  130. Volinn E, Fargo JD, Fine PG. Opioid therapy for nonspecific low back pain and the outcome of chronic work loss. Pain. 2009;142:194–201
  131. Von Korff MV, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24:521–527
  132. Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12:507–515
  133. Wastila LJ, Bishop C. The influence of multiple copy prescription programs on analgesic utilization. Journal of Pharmaceutical Care in Pain & Symptom Control. 1996;4:3–19
  134. Webster BS, Snook SH: The cost of 1989 workers' compensation low back pain claims. Spine 19:1111-1115; discussion 1116, 1994
  135. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine. 2007;32:2127–2132
  136. Webster LR. Breakthrough pain in the management of chronic persistent pain syndromes. Am J Manag Care. 2008;14:S116–S122
  137. Webster LR. Pharmacogenetics in pain management: the clinical need. Clin Lab Med. 2008;28:569–579
  138. Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9:425–432
  139. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6:432–442
  140. Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf. 2007;30:533–540

 Supported by a grant to the first author from the Milbank Foundation. A grant from The Mayday Fund supported the work necessary for this document.

PII: S1526-5900(10)00363-9

doi: 10.1016/j.jpain.2010.02.019

The Journal of Pain
Volume 11, Issue 9 , Pages 807-829 , September 2010

Article Tools

* Image Usage & Resolution